I have recently retired from a career in marketing research focusing on the Pharmacy sector. One of the realities that is rarely mentioned is that Big Pharma has come to depend on sweat equity startups to develop new products, including biologicals, and then purchase or in-licence them, even buy the company,  if they do well in early phase or even pivotal trials. Gone are the days when they took these risks. That in addition to extending patent life as noted in the article. Plus using DTC ads to push exoensive me-too or underutilized products that are subject to coinsurance vs copays, meaning far higher cost to patients. I'm glad that I worked mainly in the era of true breakthroughs and clinically meaningful blockbusters!

I have recently retired from a career in marketing research focusing on the Pharmacy sector. One of the realities that is rarely mentioned is that Big Pharma has come to depend on sweat equity startups to develop new products, including biologicals, and then purchase or in-licence them, even buy the company,  if they do well in early phase or even pivotal trials. Gone are the days when they took these risks. That in addition to extending patent life as noted in the article. Plus using DTC ads to push exoensive me-too or underutilized products that are subject to coinsurance vs copays, meaning far higher cost to patients. I'm glad that I worked mainly in the era of true breakthroughs and clinically meaningful blockbusters!

user
yes
assistant